pdufa.bio

SURF303 Phase

Page updated ·next FDA decision on the calendar ·Data as of Oct 19, 2026 8:08 PM ET

SURF303 Phase is a Tyra Biosciences, Inc. program. Its next catalyst is a Readout in Q4 2027. Every date links its source.

TYRA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Tyra Biosciences, Inc. (TYRA). Review status: Phase 2a/b in low-grade upper tract urothelial carcinoma; first patient dosed. Company guides initial results in 2027. We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027TYRA

Specialist biotech funds holding TYRA, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management12,198,625$389.6 millionfiled August 14, 2026
BVF Inc.1,476,196$47.1 millionfiled August 14, 2026
OrbiMed Advisors102,000$3.3 millionfiled August 14, 2026
Baker Bros. Advisors10,607$338,788filed August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is SURF303 Phase's next FDA decision or readout?

The next tracked catalyst for SURF303 Phase is a Readout in Q4 2027.

What happened at SURF303 Phase's most recent FDA decision?

No FDA decision for SURF303 Phase is in our archive yet.

Who makes SURF303 Phase?

Tyra Biosciences, Inc. (TYRA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.